Boston Scientific (BSX) last issued guidance on April 22, 2026 for Q2 2026. The company guided earnings per share in the range of $0.82 - $0.84, compared to a consensus EPS estimate of $0.86. Boston Scientific also guided revenue in the range of $5.34B - $5.44B for the period.
Compared to prior guidance, Boston Scientific lowered its revenue forecast from a prior range of $21.48B - $21.78B.
Boston Scientific has issued 35 guidance updates between July 27, 2022 and April 22, 2026. During this period, the company raised its outlook 13 times and lowered it 17 times, providing investors with insight into management's evolving expectations.
Review all historical guidance issued by Boston Scientific, including EPS and revenue forecasts across quarterly and annual periods.
The most recent guidance for Boston Scientific (BSX) was reported on April 22, 2026 for Q2 2026. The company provided earnings per share guidance in the range of $0.82 to $0.84, compared to the estimated EPS of $0.86. Additionally, Boston Scientific forecasted revenue between $5.34B and $5.44B for the period.
Boston Scientific (BSX) guided EPS in the range of $0.82 to $0.84 for Q2 2026. The consensus analyst EPS estimate is $0.86.
Boston Scientific (BSX) guided revenue in the range of $5.34B to $5.44B for Q2 2026.
Boston Scientific (BSX) lowered its revenue guidance from a prior range of $21.48B - $21.78B to $5.34B - $5.44B for Q2 2026.
Boston Scientific (BSX) last issued guidance on April 22, 2026 for Q2 2026.